Alstodt Amends BioRestorative Therapies Ownership Filing

TL;DR

Lance Alstodt filed an **amendment to his 13D for BioRestorative Therapies, Inc.** on Feb 13, 2024.

AI Summary

Lance Alstodt filed an Amendment No. 2 to Schedule 13D on February 15, 2024, regarding his beneficial ownership in BioRestorative Therapies, Inc. The event requiring this filing occurred on February 13, 2024. The filing pertains to Common Stock with a $.0001 par value and CUSIP 090655606. Specific changes in ownership percentages or transaction dollar amounts are not detailed in this excerpt.

Why It Matters

This amendment indicates a change in Lance Alstodt's reported beneficial ownership or intentions regarding BioRestorative Therapies, Inc., which could signal shifts in control or strategic direction for the company.

Risk Assessment

Risk Level: medium — A 13D/A filing indicates a significant shareholder's updated position, which can lead to strategic changes or activist involvement, introducing uncertainty.

Key Numbers

• $0.0001 — Par Value (Par value of BioRestorative Therapies, Inc. Common Stock)

Key Players & Entities

• Lance Alstodt (person) — Filing Person
• BioRestorative Therapies, Inc. (company) — Subject Company
• Stem Cell Assurance, Inc. (company) — Former Company Name of Subject Company
• $0.0001 (dollar_amount) — Par Value of Common Stock

FAQ

Key Financial Figures

• $1.45 — of the Company at an exercise price of $1.45 per share. The option is exercisable to

Filing Documents

• sc13da2.htm (SC 13D/A) — 42KB
• ex1.htm (EX-1) — 41KB
• 0001021771-24-000058.txt ( ) — 84KB

Security and Issuer

Item 1. Security and Issuer. This statement relates to shares of Common Stock, par value $.0001 per share (the "Common Stock"), of BioRestorative Therapies, Inc., a Nevada corporation (the "Company"). The address of the principal executive offices of the Company is 40 Marcus Drive, Suite One, Melville, New York 11747.

Identity and Background

Item 2. Identity and Background. a. Name Lance Alstodt b. Residence or Business Address 40 Marcus Drive, Suite One Melville, New York 11747 c. Occupation The Reporting Person is employed as the Chief Executive Officer, President and Chairman of the Board of the Company. d. Convictions The Reporting Person has not been convicted in a criminal proceeding in the last five years. e. Civil Judgments The Reporting Person has not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction resulting in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. f. Citizenship The Reporting Person is a citizen of the United States of America.

Source or Amount of Funds or Other Consideration

Item 3. Source or Amount of Funds or Other Consideration. N/A

Purpose of Transaction

Item 4. Purpose of Transaction. On February 13, 2024, the Company granted to the Reporting Person a ten year option for the purchase of 438,596 shares of Common Stock of the Company at an exercise price of $1.45 per share. The option is exercisable to the extent of (a) 219,298 shares effective as of the date of grant, and (b) 219,298 shares in eight equal quarterly installments commencing one year from the date of grant. Reference is made to the Incentive Stock Option Award Agreement attached hereto as Exhibit (1) for a complete description of the option granted to the Reporting Person.

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer. a. As of the date hereof, the Reporting Person is the beneficial owner of 799,136 shares of Common Stock of the Company (or approximately 11.2% of the outstanding Common Stock of the Company based upon there being 6,556,917 shares of Common Stock of the Company outstanding as of February 13, 2024, based upon the number of shares of Common Stock outstanding as of November 10, 2023, as set forth in the Company's Quarterly Report on Form 10-Q for the period ended September 30, 2023, filed with the Securities and Exchange Commission on November 13, 2023, and the number of shares of Common Stock issued pursuant to the transaction discussed in the Company's Current Report on Form 8-K for an event dated February 6, 2024, filed with the Securities and Exchange Commission on February 8, 2024). Of such number, 609,631 shares of Common Stock are issuable upon the exercise of options that are exercisable currently or within 60 days. b. The Reporting Person has sole voting and dispositive power over the 799,136 shares beneficially owned. c. During the past 60 days, the Reporting Person has not effected any transactions in the Common Stock of the Company, except as reported in Item 4 hereof.

Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. See Item 5 hereof with respect to options held by the Reporting Person.

Material to Be Filed as Exhibits

Item 7. Material to Be Filed as Exhibits. (1) Incentive Stock Option Award Agreement, dated as of February 13, 2024, between the Company and the Reporting Person. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 14, 2024 /s/ Lance Alstodt Lance Alstodt

View Full Filing

View this SC 13D/A filing on SEC EDGAR